TERN-701 Shows 64% Response Rate in Hard-to-Treat Leukemia

Terns Pharmaceuticals (TERN) announces encouraging Phase 1 results for TERN-701, showing 64% response rates in relapsed/refractory chronic myeloid leukemia patients with favorable safety profile.